Alberta’s multi year pharmacy funding framework, announced on 16 June 2026 and running to 31 March 2029, is in our view the biggest change to pharmacy economics in the province in more than a decade. Most of the coverage has been about the rules. This article is about the money: what the changes do to a pharmacy’s profit, what they do to wages and staffing, and what they do to the price a pharmacy sells for.
The short version is that the first thing to move is the EBITDA, line by line, and in different directions for different stores. We still work with a range of 5.5 to 7.0 times normalized EBITDA for established Alberta stores, but that is a brokerage working range, not a published index, and buyers may also price the new risks into the multiple or into deal terms. A store that was already run the way the framework wants stores to be run comes out ahead. A store built around the old incentives loses profit, and because value is EBITDA multiplied by 5.5 or more in that range, every dollar of lost profit takes five and a half dollars or more off the sale price.
Our guide to buying a pharmacy in Alberta covers the rules and the College process. This article assumes you know the outline and goes straight to the effect on the bottom line.
The changes, in one paragraph
Since 26 June 2026, payable pharmacy services claims have been capped at $13,000 per pharmacist in any rolling 28 day period, counted by date of service and following the pharmacist across every site where they work rather than the store. Dispensing and publicly funded vaccine assessments are excluded. Annualized, the cap is roughly $169,000 a year. On 1 October 2026 the dispensing fee rose from $12.15 to $12.35 for a days supply under 84 days and to $13.50 for 84 days or more. Also from 1 October, drugs on the Maintenance Medication List are expected to be dispensed for 84 to 100 days once a patient is stable. Shorter fills earn a fee only where the patient meets a listed criterion (prescriber direction, risk of theft or loss, facility living, medication safety concerns, or patient request for fills of 28 to 83 days), usually with a signed authorization form and, for listed drugs, an intervention code. New medications and dose changes get up to three shorter fills without the form, and residents of some continuing care settings and seniors lodges do not need the form. The detailed eligibility table is in Alberta Blue Cross Benefact 1337. Daily dispensing is now limited to one fee per patient per day, with methadone and buprenorphine/naloxone exempt. Pharmacies have until 31 October 2026 to complete the new authorization forms, and Alberta Blue Cross audits of them start on 1 November. Under Bill 11, private plans now pay first and the provincial government sponsored plans are payor of last resort. One planned change has not happened: the removal of dispensing fees on prescribed Schedule 3 and unscheduled (OTC) products, with higher allowable upcharges, was postponed by Benefact 1342 because of technical issues. Until a new date is set in a future Benefact, the pre October rules for OTC and nutritional products still apply.
Where the profit moves
A pharmacy income statement has a handful of lines that these changes touch. It helps to go through them in order.
Dispensing fee revenue on maintenance medications. This is the biggest line for most stores and the one where the direction depends entirely on how the store already operates. A stable patient on one chronic medication filled every 30 days produced twelve fees a year at $12.15, about $146. The same patient at 90 day fills produces four fees at $13.50, $54. Our examples assume drug prices stay constant and that the $100 per dispense cap on the second allowable upcharge does not bind. On expensive drugs, fewer dispenses can mean less upcharge recovered over the year, so test this on the store’s own claims. A store that moves a large share of its government plan maintenance fills from monthly to quarterly, where that is clinically appropriate and the patient agrees, loses roughly 63 percent of the fee revenue on those fills. Patients who meet a short fill criterion, with the paperwork in place, can stay on shorter fills and still generate a fee within the policy limits. A store that was already at 90 days loses nothing and gains $1.35 on every one of them.
Dispensing fee revenue on everything else. The $0.20 increase on fills under 84 days is small per fill and adds up on a high volume store. On 40,000 short fills it is $8,000 a year. It does not offset a move to 90 day fills.
Clinical services revenue. Alberta Blue Cross says most pharmacists bill about $3,000 a month in clinical services, and that the average in 2024-25 was $3,040 per pharmacist per 28 day period, well under the cap. The cap only bites in stores where one or two pharmacists bill heavily, typically an owner with Additional Prescribing Authorization who has built a large care plan and prescribing practice. In those stores, claims above $13,000 in any rolling 28 day period (roughly $169,000 a year) are paid at zero and cannot be charged to the patient, unless another pharmacist provides that care and bills it under their own ID. This is the line that changes the staffing model, covered below.
Compliance packaging. For maintenance medications, weekly blister packs requested by the patient no longer earn a fee each week. Patient request supports a fee only on fills of 28 to 83 days, with a signed form. Prescriber directed, theft or loss and facility based packaging keep a route to shorter fills, with limits on fees per 28 days and per year. Most of these routes need the signed form, though residents of some continuing care settings and seniors lodges are exempt from it. Stores with a large book of patient requested weekly packs can lose fee revenue while keeping the labour of filling the packs, which is the worst combination for the bottom line.
Daily dispensing. Methadone and buprenorphine/naloxone are exempt from the one fee limit. Another opioid dispensed daily alongside them earns a fee only under a documented protocol from an approved addiction medicine, Narcotic Transition Service or opioid transition program. Other daily dispensing drops from up to three fees a day to one, needs either a prescriber’s direction or a signed form updated every three months, and Maintenance Medication List drugs are not eligible at all. A store with a handful of daily dispensing patients outside those exemptions loses a fee line that was worth several thousand dollars per patient per year.
OTC and nutritional products (postponed). Benefact 1335 set out a change for 1 October 2026: no dispensing fee on prescribed Schedule 3 and unscheduled products under government plans, with higher allowable upcharges, and higher upcharges on nutritional products, which already carried no dispensing fee. Benefact 1342 postponed it because of technical issues, and no new date has been set. If it goes ahead as announced, a store that bills many low cost OTC fees under government plans would lose most of that fee line, with the higher upcharge recovering part of it on higher cost items. There is no dispensing fee loss on nutritional products. Treat this as a pending change and model it separately from current earnings.
Payer mix under Bill 11. For patients who hold both private coverage and provincial government plan coverage, the private plan now pays first. The effect on a store depends on how many such patients it has and on the private plans’ fee caps and markup rules. Some stores will see slightly lower fee recovery on those claims. Others will see faster payment. It is store specific and worth measuring rather than assuming.
The positive side. Certainty to 31 March 2029, the first dispensing fee increase in over a decade, and a broad schedule of paid clinical services. In our view Alberta remains one of the strongest pharmacy markets in Canada after these changes. The question is which stores in Alberta.
The wage effect: why the cap may raise pharmacist costs
The per pharmacist cap does something the other changes do not. It changes the economics of a pharmacist hour.
Before 26 June, a pharmacist with APA in a busy store could bill services with no ceiling, and the owner who held that authorization often did most of the billing personally. Services revenue was, in effect, a return on the owner’s own time. In the stores we see, the staffing model followed: one pharmacist on shift most of the day, an overlap at peak hours if the store was busy enough to justify the cost, and services fitted around dispensing.
Under the cap, each pharmacist’s payable services stop at $13,000 in any rolling 28 day period, roughly $169,000 a year, no matter how many hours they work or how many sites they work at. Services demand above that is either not paid or provided and billed by another pharmacist who actually does the work. That makes a second billing pharmacist a revenue decision, not just a workflow decision, and we expect it to affect wages in three ways.
First, it may raise demand for pharmacists who hold APA. APA is needed for the assessment for prescribing at initial access or managing ongoing therapy. Care plans, follow ups, renewals, adaptations and injections (for pharmacists authorized to inject) can be billed by any eligible pharmacist. About 66 percent of Alberta’s clinical pharmacists held APA at the end of 2025, so the supply exists, but pharmacists who can take on prescribing and care plans from their first week are now worth more to a high services store than they were in May. We expect asking rates to reflect that, especially in smaller centres where the pool is thin, although there is no wage data yet to measure it.
Second, it may raise demand for additional pharmacist hours. A store that wants to keep $250,000 of services revenue needs at least two pharmacists who each provide and bill part of that care. The cap applies to each pharmacist, not to each shift, so this does not have to mean overlap. A second pharmacist on a different shift, such as evenings or weekends, can provide eligible services too. Overlapping hours in the middle of the day are one option, useful when that is when the patients are in the store. Part time and casual pharmacists who can cover a consistent block are the people who fill that need, and there are not many of them in the markets we work in.
Third, it can raise the cost base of high services stores. For modelling we use $65 an hour, which is the $130,000 manager salary we use in Alberta normalization divided by about 2,000 paid hours a year. That is before benefits and payroll costs, so a fully loaded rate is higher. At $65, twelve added pharmacist hours a week cost $40,560 a year ($65 x 12 x 52), about $41,000 before benefits. Whether those hours pay depends on the additional services revenue actually collected, after each pharmacist’s cap, less the added wages, benefits and other costs. Demand above one pharmacist’s ceiling is not enough on its own.
For an owner, start with the data. Look at services billing by pharmacist, by date of service, since 26 June. If one pharmacist regularly reaches $13,000 in a rolling 28 day period and others are far below it, there may be care that other pharmacists could provide and bill, either in their existing hours or in added hours, and it is worth costing out. If no one is near the cap, the cap is not what limits services revenue, but that does not prove there is no unmet demand. The question then is whether added hours would bring in more paid services than they cost. Either way, each pharmacist bills only for the services they personally provide. Claims must never be submitted under another pharmacist’s ID.
For a buyer, the same data tells you whether the vendor’s services revenue depends on one person. If it does, and that person is the vendor, the revenue leaves with them unless the buyer, or a pharmacist the buyer hires, can provide those services, with APA where the service is prescribing. The cost of that hire belongs in the buyer’s normalization, and in our experience lenders increasingly put it there themselves.
A worked example: two stores, same revenue, opposite outcomes
The figures below are an illustrative scenario. They do not describe any listing, and the 6.25 multiple is our working assumption, not a market quote. The scenario covers the cap and the changes in force since 1 October 2026. It leaves out the postponed OTC change (shown separately below), compliance packaging and Bill 11 payer effects, which depend on details a short example cannot capture.
Take two Alberta community pharmacies, each with $2.4 million in revenue, about 45,000 prescriptions a year and $520,000 in normalized EBITDA before the changes. Government plans account for about 40 percent of prescriptions in both (18,000 fills), and about 60 percent of those are maintenance medications (10,800 fills). Daily dispensing claims are counted on their own line, not in these fill counts.
Store A was run on the old incentives. Most maintenance fills are monthly. The owner holds APA and billed about $190,000 in services last year, with staff pharmacists billing little. There are six daily dispensing patients outside the methadone and buprenorphine/naloxone exemption, and about 2,500 OTC fee claims a year under government plans.
Store A’s changes stack up like this. About 4,300 monthly maintenance fills for stable patients move to 90 day fills, becoming about 1,400 fills. The other 13,700 government plan fills stay under 84 days, for example because the patient meets a short fill criterion or the drug is not a maintenance medication. Each daily dispensing patient previously generated two fees a day and now generates one.
| Component | Calculation | Annual EBITDA effect |
|---|---|---|
| Fewer maintenance fills | 2,900 fewer fees x $12.15 | -$35,235 |
| Higher fee on the new 90 day fills | 1,400 x $1.35 | +$1,890 |
| Higher fee on remaining short fills | 13,700 x $0.20 | +$2,740 |
| Daily dispensing | 6 patients x 365 days x ($24.30 before less $12.35 after) | -$26,171 |
| Services above the cap | $190,000 billed less roughly $169,000 payable | -$21,000 |
| Net change | -$77,776, about -$78,000 |
The services line is a simple annualized estimate. The real test runs on each rolling 28 day period by date of service, so the actual loss depends on when the services fall and on excluded services such as publicly funded vaccine assessments. Twelve hours a week of added APA pharmacist time, at about $41,000 a year before benefits, could keep that $21,000 in the store, but it would cost more than it brings in. The owner first checks whether staff pharmacists already on shift have time to provide care plans and follow ups themselves. In this scenario they do not, so the owner lets the $21,000 go.
Net, EBITDA falls by about $78,000 to about $442,000. At the assumed 6.25 multiple, the store is worth about $2,762,500, or about $487,500 (6.25 x $78,000) less than the $3,250,000 (6.25 x $520,000) it was worth in May, before any buyer adjusts for the concentration of services billing in one person.
Not in the totals: the postponed OTC change. If the OTC change goes ahead as announced in Benefact 1335, Store A’s 2,500 government plan OTC fee claims would lose about $30,000 in dispensing fees, with perhaps $10,000 recovered through higher upcharges. That would be a further net reduction of about $20,000 a year, or about $125,000 of value at 6.25. Until Alberta Blue Cross sets a new date, this is a contingency to watch, not part of the store’s current earnings.
Store B was already run the way the framework wants. Maintenance medications have been dispensed at 90 days for years. Services billing is spread across three pharmacists, two with APA, none near the cap, and each bills only for the services they provide. OTC fee claims are minimal, and the only daily dispensing is methadone and buprenorphine/naloxone, which are exempt, with no concurrent opioid arrangements.
Store B’s changes are almost all positive. The fee increase is worth about $16,000 a year: $14,580 on its 10,800 maintenance fills at 90 days (10,800 x $1.35) and $1,440 on its 7,200 fills under 84 days (7,200 x $0.20). Small effects, such as the $0.20 increase on its daily methadone and buprenorphine/naloxone claims, are left out. Nothing else moves. EBITDA rises to about $536,000, and at 6.25 the store is worth about $3,350,000, roughly $100,000 more than it was in May.
Same revenue, same script count, same assumed multiple. Under these assumptions Store A is worth about $2,762,500 and Store B about $3,350,000, a gap of about $587,500, entirely from how the stores were run before 1 October 2026. A real store’s result depends on its own claims. This is why buyers on our files now ask for the days supply mix and services billing by pharmacist before they ask for anything else, and why our EBITDA normalization guide now needs a post framework line.
What it means for valuation
Four practical points follow.
Start with EBITDA, not the multiple. We still work with 5.5 to 7.0 times normalized EBITDA for established Alberta stores, but that range is a brokerage working assumption, not a published index, and the framework can affect the risk buyers price into a multiple as well as the earnings. In our experience, vendors who try to defend a price by arguing for a higher multiple to offset a lower EBITDA lose qualified buyers. The most productive conversation is about the EBITDA line, where the data is.
Normalization now has a new line. Alongside the $130,000 manager salary, related party wages and the usual add backs, a post framework adjustment estimates the annual EBITDA effect of the cap, the maintenance policy, daily dispensing and Bill 11 on this store, using its own claims data. The postponed OTC change belongs in a separate contingency line until it has a date. Sellers who present this adjustment themselves, with the supporting extracts, tend to control the conversation. Sellers who leave it to the buyer get the buyer’s conservative version and the lender’s more conservative version.
Concentration can be discounted twice. A store whose services revenue depends on one APA pharmacist has a revenue line that is capped by the framework and at risk from that pharmacist’s departure. Buyers can price both, through a lower EBITDA and through structure such as a holdback tied to services revenue after closing. Spreading services across pharmacists before a sale, with each pharmacist providing and billing their own work, reduces both discounts, though it does not guarantee they disappear.
Trailing twelve months is the anchor. The last fiscal year no longer describes the business. Buyers work from a TTM statement and ask for post October months as they come in. Some want to see October to December before closing or tie part of the price to those months. A seller who plans a sale for 2027 should start building the TTM now and keep the monthly extracts that support it.
What owners can do before selling
Review stable maintenance patients for 90 day fills, where it is clinically appropriate and the prescriber and the patient agree. Patients who meet a short fill criterion, with the signed form in place, can stay on shorter fills and still generate a fee within the policy limits. For the rest, the fee change applies regardless, and a store that shows the transition already complete, with the higher fee flowing, is easier for a buyer to value than one that leaves it to the buyer.
Spread services delivery. Support staff pharmacists who want to apply for APA, give them the time and the patients, and let them provide and bill the care plans, follow ups and assessments they actually perform, so that no one pharmacist carries the store. From what we see, this does more than any other single change to improve both EBITDA and the buyer’s view of risk.
Cost out added pharmacist hours honestly. Overlap or a separate shift pays only if the additional services revenue actually collected exceeds the added wages, benefits and other costs. If it does not, do not add it for the sale. Buyers can tell the difference.
Clean up the packaging book. Document the basis for every compliance packaging patient against the eligibility table in Benefact 1337: prescriber direction, risk of theft or loss, facility living, continuing care, medication safety concerns, or patient request. Most shorter fill routes need the signed authorization form, which pharmacies have until 31 October 2026 to complete, and audits start on 1 November. Patient requested weekly packs do not earn a weekly fee, so review them with the patient and the prescriber based on what the patient needs.
Keep the records. Services billing by pharmacist by 28 day period since 26 June, days supply mix, packaging basis, daily dispensing split, and payer mix, all as extracts a buyer’s accountant can tie to the general ledger.
What buyers can do
Build the model from the store’s own data, not from the province’s averages. Test services revenue against the cap using your staffing plan and dated claims, not the vendor’s annual total. Cost any added pharmacist hours your plan needs into normalization. Run a downside case on the maintenance policy using the days supply mix, and keep the postponed OTC change as a separate scenario. Then bring the model to the vendor as a basis for structure rather than a basis for argument. In our experience the vendors who engage with a buyer’s model are more likely to close, and buyers who bring one often get better terms from the lender.
If you own an Alberta pharmacy and want a view on what the framework does to your number, or you are a buyer working through an Alberta model, our Alberta pharmacy market page has the current picture and you can contact us for a confidential conversation.